PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma
This is a multicenter, single-arm, open-label phase II study to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in the first-line treatment of subjects with inoperable HCC.
Hepatocellular Carcinoma
BIOLOGICAL: PM8002|DRUG: FOLFOX regimen
Objective Response Rate, Objective response rate (ORR) is the proportion of subjects with complete response (CR) or partial response (PR), based on RECIST v1.1., Up to approximately 2 years
PM8002 is a Bispecific Antibody Targeting PD-L1 and VEGF.